Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Biolase Gets Australian Therapeutic Goods Administration Approval For Its Waterlase Solid-State Dental Laser System

https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=405308&agid=(PrintDetailsPublic)&actionid=1
byHappy Mohamed
February 24, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=405308&agid=(PrintDetailsPublic)&actionid=1

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer; Primary Endpoint Met

By Charles Gross
November 10, 6:28 PM
NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease. These positive data form the basis of ImmunityBio's BLA for BCG-unresponsive NMIBC CIS, which the FDA accepted for review in July 2022.

IBRX